Many Ways To Play This Zika Powerhouse!
With everyone from the Wall Street Journal to Zacks talking about Spotlight Innovation Inc. (STLT) lately I’m tickled we got into it when we did.
It seems like every day is another leap for this chart and the action is taking shares out of our normal comfort zone at a mighty fast rate.
Today, for instance, the BOTTOM is up 27% from yesterday. That’s the kind of move that tells me that STLT is getting up nerve to raise the roof!
When that happens, I don’t know how long us penny traders will be able to keep playing with STLT before bigger boys muscle in. Time COUNTS here!
And here and now, there’s room in those giant stairsteps to heaven to earn a little happy happy inside the moves:
You know the drill. Look for soft points as your entries, stay within the candle while it lasts, ride the breakout moves when they come.
Right here, STLT is still a healthy 2 digits from the recent $1 barrier so there’s room for the lazy. And the dips are deep enough to grease an entry.
Some of you might have gotten STLT below $0.80 this morning and cashed in closer to $0.90. That’s how it works.
Naturally, when you see a full-fledged BREAKOUT, that ceiling looks vulnerable. Smash it, who knows where STLT can take us?
Meanwhile, the news spreads. Remember the ebola scare a couple years ago? Stocks to detect and cure it went on a 50%-70% bull run.
Now we’re looking at ZIKA coming to America and $500 MILLION has already been diverted to fight the new kid in virus town.
STLT was mighty quiet before last week, when the International Congress of Immunology delivered chilling news.
Turns out the bug experts warn 90 MILLION women could catch the virus before a cure emerges . . . and the clock is ticking fast!
Wall Street could smell the dollars ramping up behind zika research. STLT pinged the radar, these shares went ballistic overnight.
Before the conference, STLT was chirping along at maybe $0.35. The company was on a long ramp, minding its own business.
Now, I’m actually a little speechless on that chart. The last three days here have been miraculous, some of the strongest action I’ve seen in ages.
RSI is buried in the green, about as strong as it gets with lots of time before it comes back down below 70 and lets the market know “overbought.”
MACD through the roof, volume ramping up nice as word of what STLT does spreads around Wall Street. Still early stages but WOW, bull signal galore!
Now how did tiny little STLT get a zika platform that gets the world to sit up and take notice? They’re what you call opportunistic.
Instead of chasing brand-new drugs like the giants, STLT runs screens that match existing drugs to new diseases. It’s kind of famous science now.
Heck, here’s the WALL STREET JOURNAL talking about STLT as a company leading the race toward a zika cure!
We rarely run in the same crowd as the mighty WSJ so it’s something rare and special to get a link like that.
I think the fame is catching management a little by surprise. Here they were last year introducing new shareholders to their drug-matching approach.
Now it’s a shame so many pups die that way, but while veterinary pharma is becoming huge, it’s not exactly a blockbuster catalyst yet.
Curing HUMAN cancer with off-the-rack antibodies is a whole different ball game, but even that prospect was a slow burn for months!
But STLT screens more recently found fixings for a zika cure. Peer-reviewed and everything! That’s what it takes to really make Wall Street purr!
ZACKS picked up the flag yesterday and started waving it. Big partnerships. Buzz here is already getting noisy . . . last shot for penny traders?
Don’t miss the STLT party while us basement types can still get in!
Happy, Happy, Happy Trading!
Listen pal there’s a lot of legal stuff you need to know so grab a cup of coffee and read this in its entirety. The content of this e-mail is paid advertising not a recommendation nor an offer to buy or sell securities. .com as well as this newsletter (hereafter called “SC”) is an information and marketing firm wholly owned by Third Coast Media, LLC and is not a financial analyst, investment adviser or broker/dealer. SC is in the business of marketing and advertising companies to generate exposure of them by sending alerts to our subscribers for monetary compensation. Third Coast Media, LLC has been compensated twenty thousand dollars from a non-disclosed third party for STLT advertising and promotional services. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only.
I am a simple man, and not a very smart one at that! Anyone viewing this newsletter should assume the hiring party or affiliates of the hiring party own shares of the company mentioned which they plan to liquidate, further understanding that the liquidation of those shares may or may not negatively impact the share price. Just a part of life, partner.
Like most things in life, investing in securities is highly speculative and carries a great deal of risk. It is not for an amateur or the faint of heart! You may lose your entire investment. If you cannot afford to lose your entire investment do NOT invest in securities. Maybe you should drink shirley temples and stuff your mattress with piles of green instead? Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. We are advertisers, not investors or traders so you should never listen to anything we say.
We try to never make up information, though mistakes can occasionally happen. This report is based entirely upon information gathered from public information and third party websites and is sourced as much as possible. Although the information contained in this e-mail is believed to be reliable, we make no warranties as to the accuracy of the content of this e-mail, and expressly disclaim and accept no liability for how readers may choose to utilize the content of this e-mail.
Readers are strongly urged to independently verify all statements made in this advertisement and to perform their own due diligence on this or any other advertised company. You should go as far as to assume all information in our communications is incorrect until you personally verify the information, and again are encouraged to never invest just based on the information contained in our written communications. This report contains forwardlooking statements about the featured company within the meaning of the law.